Hygieia Biopharma develops small interfering RNA (siRNA) drugs using proprietary delivery platforms, including the MVIP and DDP technologies, to target and inhibit cancer-related gene expression. The company addresses the need for effective treatments for chronic diseases, particularly in oncology and liver-related conditions, by enhancing siRNA stability and delivery efficiency.
Funding
Funding not disclosed
Founders
Product
Problem
Many chronic diseases, particularly in oncology and liver-related conditions, lack effective treatments due to challenges in delivering therapeutic molecules to target cells and tissues. Traditional siRNA drugs often suffer from poor stability and inefficient delivery, limiting their therapeutic potential.
Solution
Hygieia Biopharma develops innovative small interfering RNA (siRNA) drugs designed to address the limitations of existing therapies. The company utilizes proprietary delivery platforms, including MVIP and DDP technologies, to enhance siRNA stability and delivery efficiency. The MVIP platform, a GalNAc-siRNA delivery technology, improves siRNA stability and delivery efficiency. The DDP platform enables the simultaneous delivery of multiple siRNAs, allowing for the development of drugs targeting complex diseases mediated by multiple targets and mechanisms. Hygieia Biopharma is also developing the NSDP platform for siRNA delivery to the central and peripheral nervous systems.
Target Audience
The primary target audience includes patients suffering from chronic diseases with unmet medical needs, as well as pharmaceutical companies seeking innovative siRNA therapeutics and delivery technologies.
Features
- MVIP (Multi-Valency In Parallel) delivery platform for enhanced siRNA stability and efficient delivery to the liver
- DDP (Dual Delivery Platform) technology for simultaneous delivery of two or more siRNAs to address multi-target diseases
- NSDP delivery platform for targeting the central and peripheral nervous systems
- siRNA drugs targeting liver-related diseases, cardiovascular and metabolic diseases, complement-mediated diseases and nervous system diseases
- End-to-end siRNA drug development platform, from target discovery to clinical proof-of-concept